Answers are grounded in this paper and cite their sources.
Heart transplantation is widely regarded as the most effective and durable treatment option for patients with advanced/terminal cardiac failure. However, the need for organs by far surmounts the donations and the corresponding long waiting lists carry a considerable mortality. Currently, mechanical assist devices are the major alternative, but they come with a high complication rate and only moderate improvements in patients’ quality of life. An emerging and promising solution is xenotransplantation of genetically multi-modified (GM) pig hearts. Recent studies have shown long-term success in baboons with both heterotopic (non-life-supporting) abdominal and life-supporting orthotopic porcine heart transplants. Notably, in a recent case of compassionate use, a pig heart with ten genetic modifications was implanted into a terminally ill patient, who survived for two months. This review examines the concept of pig heart xenotransplantation, focusing on challenges such as immune rejection, coagulation dysregulation, and detrimental overgrowth of the transplanted heart; GM strategies and the non-nephrotoxic immunosuppression are discussed to minimize or prevent these issues. This review covers also microbiological (virologic) safety considerations and further requirements for initiating clinical studies.
No takes yet. Share an insight, caveat, or question.
Wolf et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: